A Comprehensive Optical Blood Pressure Assessment Tool to Identify Cases of Unscreened Hypertension Across an Active Population in the U.S.
← catalyst calendarSponsored by Nucor (industry) · NUE — their whole pipeline →.
Phase
—
Status
Withdrawn
Study type
Observational
Enrollment
0actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was aborted by the sponsor.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-16 | estimated | When the study began enrolling |
| Primary completion | 2025-07-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypertension
Intervention
- Device: Optical Blood Pressure Monitoring Device (Aktiia G1)
Primary outcome
what the primary-completion date above is the date OFThe percentage of subjects with undiagnosed hypertension
measured Each participant will wear the device continuously for 28 days.
Permalink · NUE's whole pipeline · Catalyst calendar · Every registered study · What changed